A one pot synthesis of a mixed macrocycle of resorcinol and pyrogallol is disclosed using an acidic catalyst by conventional as well as by microwave assisted methods. Compared with traditional synthesis, the microwave mediated tactic provides a simple, greener route and affords higher compound yields in a shorter period. Moreover, the catalyst can be efficiently reused without any loss in activity.

A one pot synthesis of a mixed macrocycle of resorcinol and pyrogallol is disclosed using an acidic catalyst by conventional as well as by microwave assisted methods. Compared with traditional synthesis, the microwave mediated tactic provides a simple, greener route and affords higher compound yields in a shorter period. Moreover, the catalyst can be efficiently reused without any loss in activity.

A cocrystal complex of pirfenidone with a polyphenolic macrocycle host is disclosed. The composition is useful, in some embodiments, as an acne treatment. In one embodiment, the macrocycle is calixarene or a calixarene derivative. In another embodiment, the macrocycle is resorcin[4]arene. In one embodiment, the macrocycle is C-methylresorcin[4]arene (RsC1). In another embodiment, the macrocycle is C-butylresorcin[4]arene (RsC4).

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease.

##STR00001##

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a —(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease.

##STR00001##

A curable composition and a permanent resist film made using this curable composition are provided. The composition dissolves well in solvents, gives coatings superior in alkali developability, thermal decomposition resistance, light sensitivity, and resolution, and is particularly suitable for the formation of permanent resist films. Specifically, the composition is a curable composition for permanent resist films and contains a phenolic hydroxyl-containing compound (A) that has a molecular structure represented by structural formula (1):

##STR00001##

(where R.sup.1 is hydrogen, alkyl, or aryl, and n is an integer of 2 to 10; R.sup.2 is alkyl, alkoxy, aryl, aralkyl, or halogen, and m is an integer of 0 to 4; if m is 2 or more, the plurality of R.sup.2s may be the same or different from one another, and may be bonded to either of the two aromatic rings in the naphthylene structure) and a photosensitizer (B1) or curing agent (B2).

Disclosed is a novel stabilizer represented by formula I,

##STR00001##

Further disclosed is a liquid crystal composition comprising a compound of formula I. The liquid crystal composition disclosed in the present invention has a low viscosity γ.sub.1, a moderate dielectric anisotropy Δ∈, a moderate optical anisotropy Δn, and most principally a high reliability, and can achieve a quick response of liquid crystal display.

Disclosed is a novel stabilizer represented by formula I,

##STR00001##

Further disclosed is a liquid crystal composition comprising a compound of formula I. The liquid crystal composition disclosed in the present invention has a low viscosity γ.sub.1, a moderate dielectric anisotropy Δ∈, a moderate optical anisotropy Δn, and most principally a high reliability, and can achieve a quick response of liquid crystal display.

This invention provides for a unit dosage form of treprostinil at a dosage of between 0.1 mg/mL and 25 mg/mL in a sterile fluid composition formulated for subcutaneous or intravenous injection, which composition does not comprise an antimicrobial preservative. Selectively activatable patch-pump assemblies comprising a sealed prefilled drug-reservoir containing the unit dosage form is described as are methods for reducing pain at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof, and methods of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof. The invention also provides a method of treating pulmonary hypertension, and methods for treating, or reducing the severity or reducing the pathogenesis of Pulmonary arterial hypertension (PAH) in a subject making use of the compositions as herein described.

This invention provides for a unit dosage form of treprostinil at a dosage of between 0.1 mg/mL and 25 mg/mL in a sterile fluid composition formulated for subcutaneous or intravenous injection, which composition does not comprise an antimicrobial preservative. Selectively activatable patch-pump assemblies comprising a sealed prefilled drug-reservoir containing the unit dosage form is described as are methods for reducing pain at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof, and methods of reducing irritation, inflammation or a combination thereof at a site of subcutaneous or intravenous infusion of treprostinil in a subject in need thereof. The invention also provides a method of treating pulmonary hypertension, and methods for treating, or reducing the severity or reducing the pathogenesis of Pulmonary arterial hypertension (PAH) in a subject making use of the compositions as herein described.